NATCO Pharma Limited share price

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Agrochemicals. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroente…Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - Specialty & GenericNifty 500 Nifty Smallcap 250NSE: NATCOPHARMISIN INE987B01026

16 Oct 2026, 3:30 PM IST₹785.05▲ 0.10 (0.01%)

Market Cap₹ 14,445 Cr.
Current Price₹ 785.05
High / Low₹ 1,227 / 779
Stock P/E12.4
Book Value₹ 515
Dividend Yield0.76 %
ROCE16.1 %
ROE16.90 %
Face Value₹ 2.0

More figures (10)

EPS (TTM)₹ 63.37
Price / Book1.52
OPM31.1 %
Debt / Equity0.08
Sales growth (5Y)14.7 %
Profit growth (5Y)26.2 %
Promoter holding50.9 %
EV / EBITDA11.8
Beta0.15
All-time high₹ 1,639

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
NATCOPHARM	-3.47%	-18.75%	-27.77%	-13.07%	-4.48%	-2.22%	-2.48%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

NATCO Pharma Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹14,445 crore.
It trades at 12.4 times its last 12 months' earnings and 1.5 times book value.
Revenue grew 14.7% a year over the last 5 years, profit 26.2% a year.
Return on equity was 16.9% and return on capital employed 16.1% in the latest year.
Debt was 0.08 times shareholders' equity.
The share price is 36.0% below its 52-week high and down 4.5% over one year.
Promoters and insiders hold about 50.9%; institutions about 13.4%.

Pros

Strong return on equity: 23.6% on average over the last 3 years.
Company is almost debt-free (debt is 0.08 times equity).
Profit has grown 26.2% a year over the last 5 years.

Cons

Latest quarter (Jun 2026): profit fell 57% from a year ago.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About NATCO Pharma Limited

Employees: 4,433
Head office: Hyderabad
NSE industry: Healthcare

HealthcareHealthcareDrug Manufacturers - Specialty & Generic

Part ofNifty 500 Nifty Smallcap 250

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	NATCO Pharma	785.05	12.4	14,445	0.76	207	-57.01	735	-44.68	16.1	16.9	1.52	31.1	0.08	50.88	4,078	14.7
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,921	54.85	9.1	27.1	18.39	25.0	1.79	63.18	13,980	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	3.8
7.	Cipla	1,325.10	31.8	1,07,051	0.98	786	-39.18	7,119	2.33	14.9	11.8	3.11	17.5	0.02	31.13	28,163	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Aurobindo Pharma	1,666.90	26.0	95,910	0.00	1,033	14.29	9,106	8.65	13.5	9.9	2.56	15.6	0.21	54.79	33,385	10.7
10.	Mankind Pharma	2,275.50	46.0	93,988	0.00	574	29.12	4,031	12.89	13.7	12.5	5.76	19.9	0.39	75.39	14,278	17.7
	Median: 60 Co.	1,712.85	34.1	11,251	0.18	680	8.79	6,020	15.68	15.5	12.9	3.99	15.2	0.21	53.40	20,499	11.2

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	1,141	1,031	759	1,068	1,363	1,371	475	1,221	1,329	1,363	647	739	735
YOY Sales Growth %	28.93%	138.69%	54.03%	18.98%	19.47%	32.94%	-37.41%	14.29%	-2.47%	-0.59%	36.33%	-39.47%	-44.68%
	613	573	491	571	558	567	436	673	758	784	489	612	549
Material Cost %	17%	21%	21%	13%	13%	13%	17%	20%	18%	12%	21%	21%	20%
Employee Cost %	12%	12%	16%	13%	10%	11%	30%	13%	13%	15%	25%	21%	24%
Other Expenses %	24%	23%	27%	27%	17%	17%	45%	22%	27%	30%	30%	40%	30%
Operating Profit	528	458	268	497	805	804	39	548	571	579	159	128	187
OPM %	46%	44%	35%	47%	59%	59%	8%	45%	43%	42%	25%	17%	25%
Other Income	20	29	37	42	48	64	176	66	62	100	58	78	59
Interest	4	4	5	6	5	4	4	10	3	13	10	11	13
Depreciation	44	44	44	56	44	46	47	98	58	52	46	50	47
Profit before tax	500	440	256	478	804	818	164	506	572	614	161	144	186
	16%	16%	17%	19%	17%	17%	19%	20%	16%	16%	13%	-62%	34%
Current tax	92	82	52	90	144	154	34	106	116	140	31	16	49
Deferred tax	-12	-11	-9	1	-9	-12	-2	-7	-24	-45	-11	-105	15
	420	369	213	386	669	677	132	406	480	518	151	269	207
Profit from associates											11	36	84
Minority share						-1	-1	-1	-0	-1	-0	1
Profit to shareholders	420	369	213	386	669	677	133	407	481	518	152	268	207
YOY Profit Growth %	31.18%	549.65%	241.41%	40.07%	59.05%	83.33%	-37.75%	5.10%	-28.15%	-23.44%	14.27%	-33.74%	-57.01%
EPS in Rs	23.26	20.60	11.88	21.56	37.32	37.81	7.43	22.70	26.84	28.94	8.46	14.96	11.53
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	1,048	931	625	965	1,237	1,293	408	1,157	1,193	1,264	529	609	597
YOY Sales Growth %	30.11%	165.02%	51.40%	23.50%	17.99%	38.91%	-34.82%	19.96%	-3.57%	-2.19%	29.74%	-47.40%	-49.98%
	545	488	387	512	474	502	378	596	653	712	409	516	491
Material Cost %	17%	19%	18%	11%	12%	12%	17%	19%	15%	12%	21%	20%	26%
Employee Cost %	11%	11%	17%	13%	10%	10%	30%	12%	12%	14%	26%	22%	25%
Other Expenses %	24%	22%	28%	29%	17%	17%	45%	20%	27%	30%	30%	43%	31%
Operating Profit	504	442	238	453	763	791	29	561	540	553	120	92	106
OPM %	48%	48%	38%	47%	62%	61%	7%	48%	45%	44%	23%	15%	18%
Other Income	15	25	30	36	40	51	168	62	60	93	55	73	48
Interest	3	3	4	5	4	3	3	9	3	12	8	10	10
Depreciation	40	40	40	52	40	42	44	94	54	48	42	46	43
Profit before tax	475	424	224	433	758	797	150	521	543	586	125	110	102
	15%	15%	14%	19%	16%	17%	17%	18%	15%	15%	15%	-91%	27%
Current tax	84	75	42	84	132	148	28	99	106	131	26	6	11
Deferred tax	-14	-12	-11	-0	-11	-12	-3	-7	-27	-46	-8	-105	16
	405	360	192	349	636	661	125	428	464	501	107	210	75
YOY Profit Growth %	31.59%	855.44%	414.75%	37.39%	56.99%	83.54%	-34.95%	22.63%	-27.06%	-24.23%	-14.41%	-51.04%	-83.93%
EPS in Rs	22.43	20.11	10.72	19.49	35.53	36.91	6.97	23.90	25.91	27.97	5.97	11.70	4.17
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	2,202	2,095	1,915	2,052	1,945	2,707	3,999	4,430	4,078	3,485
YOY Sales Growth %		-4.88%	-8.57%	7.16%	-5.23%	39.20%	47.72%	10.77%	-7.93%
	1,274	1,300	1,332	1,446	1,681	1,772	2,247	2,234	2,642	2,433
Material Cost %	19%	17%	20%	25%	29%	23%	18%	16%	17%	17%
Employee Cost %	15%	17%	20%	20%	23%	18%	13%	13%	17%	20%
Other Expenses %	24%	28%	30%	25%	35%	24%	25%	21%	31%	32%
Operating Profit	928	795	583	606	264	936	1,751	2,196	1,437	1,052
OPM %	42%	38%	30%	30%	14%	35%	44%	50%	35%	30%
Other Income	40	130	107	104	99	105	128	355	298	295
Interest	15	19	22	13	18	15	19	24	37	47
Depreciation	66	81	100	117	143	164	187	235	207	196
Profit before tax	887	825	569	580	202	862	1,674	2,291	1,491	1,105
	22%	22%	19%	24%	16%	17%	17%	18%	8%	8%
Current tax	220	188	131	141	48	163	317	438	304
Deferred tax	-28	-6	-21	-4	-16	-16	-31	-30	-185
	695	642	458	442	170	715	1,388	1,883	1,419	1,145
Profit from associates									47	131
Minority share	-1	-2	-3	2				-2		0
Profit to shareholders	696	644	461	441	170	715	1,388	1,885	1,419	1,144
YOY Profit Growth %		-7.59%	-28.69%	-3.43%	-61.57%	320.76%	94.09%	35.66%	-24.68%
EPS in Rs	39.26	34.98	25.33	24.20	9.32	39.18	77.34	105.26	79.20	63.89
Dividend Payout %						14%	12%	6%	6%

Compounded Sales Growth

5 Years:: 15%
3 Years:: 15%
TTM:: -21%

Compounded Profit Growth

5 Years:: 26%
3 Years:: 26%
TTM:: -32%

Stock Price CAGR

5 Years:: -2%
3 Years:: -2%
1 Year:: -4%

Return on Equity

4 Years:: 21%
Last Year:: 17%

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	2,109	1,986	1,790	1,654	1,768	2,351	3,569	4,095	3,595	2,999
YOY Sales Growth %		-5.80%	-9.87%	-7.64%	6.91%	32.99%	51.80%	14.73%	-12.21%
	1,180	1,170	1,212	1,236	1,555	1,506	1,932	1,950	2,290	2,127
Material Cost %	18%	17%	22%	30%	30%	23%	16%	14%	16%	18%
Employee Cost %	15%	17%	20%	23%	23%	18%	13%	13%	16%	20%
Other Expenses %	23%	25%	26%	22%	35%	23%	25%	21%	31%	33%
Operating Profit	928	817	578	418	213	845	1,637	2,144	1,305	871
OPM %	44%	41%	32%	25%	12%	36%	46%	52%	36%	29%
Other Income	39	130	124	101	95	86	105	321	281	270
Interest	15	19	21	11	13	9	15	20	32	39
Depreciation	66	80	98	115	138	151	172	220	190	179
Profit before tax	888	847	583	392	156	771	1,555	2,226	1,364	923
	21%	21%	19%	21%	11%	17%	16%	17%	6%	3%
Current tax	217	186	129	86	33	133	285	408	268
Deferred tax	-28	-6	-21	-4	-16	1	-36	-32	-186
	698	667	475	310	139	637	1,307	1,850	1,282	892
YOY Profit Growth %		-4.45%	-28.87%	-34.77%	-55.06%	358.02%	105.09%	41.62%	-30.74%
EPS in Rs	39.38	36.22	26.08	16.99	7.63	34.90	72.79	103.31	71.55	49.81
Dividend Payout %						16%	13%	6%	7%

Compounded Sales Growth

5 Years:: 17%
3 Years:: 15%
TTM:: -26%

Compounded Profit Growth

5 Years:: 33%
3 Years:: 26%
TTM:: -47%

Stock Price CAGR

5 Years:: -2%
3 Years:: -2%
1 Year:: -4%

Return on Equity

4 Years:: 21%
Last Year:: 17%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	37	36	36	36
Reserves	4,837	5,817	7,571	9,185
	176	371	279	714
Long term borrowings				100
Short term borrowings	174	363	273	606
	608	682	744	1,139
Trade payables	264	236	275	409
Minority interest			5
Current liabilities	683	973	944	1,681
Total Liabilities	5,657	6,906	8,631	11,074
	2,330	2,504	2,706	2,909
Gross block	3,243	3,568	3,956	4,264
Accumulated depreciation	912	1,064	1,250	1,355
Goodwill & intangibles	188	193	266	257
CWIP	91	206	274	363
	3,236	4,196	5,651	7,802
Inventories	743	701	766	909
Trade receivables	856	1,189	1,247	881
Cash & equivalents	132	70	120	199
Current assets	3,000	4,024	5,270	5,052
Total Assets	5,657	6,906	8,631	11,074

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	849	1,212	1,697	1,768
Profit for the year	715	1,388	1,885	1,419
Working capital changes	63	-309	-200	646
Direct taxes paid	-178	-286	-373	-398
	-477	-1,033	-1,415	-2,082
Fixed assets purchased	-206	-359	-512	-391
Fixed assets sold	31	2	95	1
Investments purchased	-536	-1,186	-2,397	-5,740
Investments sold	109	582	1,293	6,081
	-363	-247	-211	298
Proceeds from borrowings				400
Interest paid	-14	-18	-18	-36
Dividends paid	-100	-171	-108	-90
Net Cash Flow	9	-68	72	-16
Free Cash Flow	644	853	1,185	1,377

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	14.7%	25.9%	28.0%	16.9%
ROCE	17.5%	28.4%	30.0%	16.1%
Operating margin	29.3%	39.6%	44.9%	31.1%
Net margin	26.5%	34.9%	42.7%	35.1%
Debt / equity	0.04	0.06	0.04	0.08
Current ratio	4.39	4.14	5.59	3.01
Debtor days	116	109	103	80
Inventory days	364	296	323	360
Days payable	129	100	116	162
Cash conversion cycle	351	305	310	278
Working capital days	314	280	358	304

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 49.39%
FIIs 16.00%
DIIs 6.16%
Public 28.45%

%	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	49.71%	49.71%	49.71%	49.62%	49.62%	49.56%	49.56%	49.48%	49.48%	49.42%	49.42%	49.39%
	13.72%	16.14%	17.45%	17.51%	17.94%	17.49%	15.51%	14.09%	15.16%	17.37%	16.99%	16.00%
Foreign portfolio investors (Cat. I)	13.37%	15.57%	16.96%	16.66%	17.26%	16.88%	15.20%	13.78%	14.82%	16.96%	16.55%	15.56%
Foreign portfolio investors (Cat. II)	0.35%	0.57%	0.49%	0.85%	0.68%	0.61%	0.32%	0.31%	0.34%	0.41%	0.44%	0.43%
	11.25%	9.70%	7.87%	6.75%	5.57%	5.65%	5.82%	5.87%	5.39%	5.46%	5.62%	6.16%
Mutual funds	5.20%	4.08%	2.67%	2.37%	1.92%	1.85%	2.11%	2.20%	1.60%	1.72%	1.92%	2.25%
Insurance companies	6.04%	5.58%	5.09%	4.23%	3.33%	3.39%	3.43%	3.31%	3.50%	3.27%	3.64%	3.80%
Banks										0.03%
Alternative investment funds	0.02%	0.03%	0.10%	0.15%	0.33%	0.23%	0.10%	0.36%	0.28%	0.43%	0.06%	0.10%
	25.32%	24.45%	24.97%	26.12%	26.87%	27.29%	29.11%	30.56%	29.96%	27.75%	27.97%	28.45%
Retail (up to ₹2 lakh)	17.18%	17.09%	18.11%	19.25%	19.67%	20.03%	21.88%	22.27%	21.99%	20.13%	20.16%	20.64%
HNIs (above ₹2 lakh)	4.06%	3.52%	3.48%	3.35%	3.67%	3.65%	3.34%	3.57%	3.39%	3.20%	3.25%	3.22%
NRIs	1.30%	1.32%	1.28%	1.28%	1.37%	1.41%	1.44%	1.64%	1.70%	1.69%	1.70%	1.72%
Bodies corporate	2.22%	1.96%	1.54%	1.68%	1.60%	1.64%	1.88%	1.63%	1.41%	1.37%	1.53%	1.59%
IEPF	0.47%	0.47%	0.48%	0.47%	0.48%	0.48%	0.50%	0.49%	0.50%	0.49%	0.48%	0.48%
No. of Shareholders	2,07,571	2,28,467	2,51,485	3,02,944	3,45,332	4,05,222	4,29,434	4,19,699	4,24,167	4,10,970	4,03,166	4,04,135

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Mutual funds & institutions holding NATCO Pharma

Holder (above 1%)	Stake
Life Insurance Corporation Of IndiaInsurance	2.24%
Tata Value FundMutual fund	1.03%

As named in the shareholding pattern for Sep 2026 filed with NSE; mutual funds together hold 2.25% of the company. Shareholders below 1% are not named in the filing.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Credit RatingNatco Pharma Limited has informed the Exchange about Credit Rating29-Nov-2025

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Results announced: 12 Nov 2026
Ex-dividend date: 20 Aug 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

Natco Pharma Limited (NSE: NATCOPHARM) Approves ₹1,279.36 Crore Rights IssueKalkine India · 25 Sep 2026

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about NATCO Pharma Limited

What is the share price of NATCO Pharma Limited today?

NATCO Pharma Limited (NATCOPHARM) last traded at ₹785.05 on NSE (16 Oct 2026, 3:30 PM IST). Prices may be delayed.

What is the market cap of NATCO Pharma Limited?

About ₹14,445 crore at the latest price.

What is the P/E ratio of NATCO Pharma Limited?

About 12.4 times its earnings over the last 12 months.

Is NATCO Pharma Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy NATCO Pharma Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

NATCO Pharma Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About NATCO Pharma Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Mutual funds & institutions holding NATCO Pharma

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about NATCO Pharma Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next